Danni Li1, Jeffrey R Misialek2, Fangying Huang1, Gwen B Windham3, Fang Yu4, Alvaro Alonso5. 1. Department of Lab Medicine and Pathology, University of Minnesota, Minneapolis. 2. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis. 3. Department of Medicine, University of Mississippi Medical Center, Jackson. 4. School of Nursing, University of Minnesota, Minneapolis. 5. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Abstract
Background: Plasma metabolites such as phosphatidylcholines and sphingomyelins (SMs) are associated with an age-related cognitive decline. However, their relations to age-related physical function decline remain largely unknown. Methods: We examined the cross-sectional relations of 12 plasma metabolites (including four phosphatidylcholines and four SMs) with physical function in 383 older adults in the At herosclerosis Risk in Communities Study at the fifth exam (2011-2013, mean age [standard deviation (SD)]: 78.0 [5.5], 54.4% women, 28.3% African Americans). Physical function was assessed using grip strength, Short Physical Performance Battery, and 4-m walking speed. Individual metabolites were log-transformed and standardized. Multivariable linear regression was performed to account for demographics, APOE genotype, cardiovascular risk factors, comorbidities, use of antihypertensive and lipid-lowering medications, depressive symptoms, and cognition. Results: Lower concentrations of asymmetric dimethylarginine and higher concentrations of SM (OH) C22:1, SM (OH) C22:2, and SM (OH) C24:1 were associated with physical function measures. In particular, SM (OH) C22:1 and SM (OH) C24:1 were associated with all three measures of physical function: β-coefficients (95% confidence interval) with grip strength were 0.89 kg (0.00, 1.78) and 0.86 kg (0.10, 1.61) per 1 SD higher concentration, respectively; with Short Physical Performance Battery score, were 0.61 (0.34, 0.88) and 0.41 (0.19, 0.63) per 1 SD difference, respectively; with 4-m walking speed were 0.035 m/s (0.013, 0.056) and 0.035 m/s (0.028, 0.047), respectively. Conclusions: Plasma SM (OH)s may be independently associated with physical function in older adults.
Background: Plasma metabolites such as phosphatidylcholines and sphingomyelins (SMs) are associated with an age-related cognitive decline. However, their relations to age-related physical function decline remain largely unknown. Methods: We examined the cross-sectional relations of 12 plasma metabolites (including four phosphatidylcholines and four SMs) with physical function in 383 older adults in the At herosclerosis Risk in Communities Study at the fifth exam (2011-2013, mean age [standard deviation (SD)]: 78.0 [5.5], 54.4% women, 28.3% African Americans). Physical function was assessed using grip strength, Short Physical Performance Battery, and 4-m walking speed. Individual metabolites were log-transformed and standardized. Multivariable linear regression was performed to account for demographics, APOE genotype, cardiovascular risk factors, comorbidities, use of antihypertensive and lipid-lowering medications, depressive symptoms, and cognition. Results: Lower concentrations of asymmetric dimethylarginine and higher concentrations of SM (OH) C22:1, SM (OH) C22:2, and SM (OH) C24:1 were associated with physical function measures. In particular, SM (OH) C22:1 and SM (OH) C24:1 were associated with all three measures of physical function: β-coefficients (95% confidence interval) with grip strength were 0.89 kg (0.00, 1.78) and 0.86 kg (0.10, 1.61) per 1 SD higher concentration, respectively; with Short Physical Performance Battery score, were 0.61 (0.34, 0.88) and 0.41 (0.19, 0.63) per 1 SD difference, respectively; with 4-m walking speed were 0.035 m/s (0.013, 0.056) and 0.035 m/s (0.028, 0.047), respectively. Conclusions: Plasma SM (OH)s may be independently associated with physical function in older adults.
Authors: Kathleen A Potter; Michael J Kern; George Fullbright; Jacek Bielawski; Steven S Scherer; Sabrina W Yum; Jian J Li; Hua Cheng; Xianlin Han; Jagadish Kummetha Venkata; P Akbar Ali Khan; Bärbel Rohrer; Hiroko Hama Journal: Glia Date: 2011-04-13 Impact factor: 7.452
Authors: Christina M Parrinello; Pamela L Lutsey; Christie M Ballantyne; Aaron R Folsom; James S Pankow; Elizabeth Selvin Journal: Am Heart J Date: 2015-04-18 Impact factor: 4.749
Authors: Michelle M Mielke; Veera Venkata Ratnam Bandaru; Norman J Haughey; Peter V Rabins; Constantine G Lyketsos; Michelle C Carlson Journal: Neurobiol Aging Date: 2008-05-05 Impact factor: 4.673
Authors: Markus C Stühlinger; Roberta K Oka; Eric E Graf; Isabella Schmölzer; Barbara M Upson; Om Kapoor; Andrzej Szuba; M Rene Malinow; Thomas C Wascher; Otmar Pachinger; John P Cooke Journal: Circulation Date: 2003-08-11 Impact factor: 29.690
Authors: Aozhou Wu; Josef Coresh; Elizabeth Selvin; Hirofumi Tanaka; Gerardo Heiss; Alan T Hirsch; Bernard G Jaar; Kunihiro Matsushita Journal: J Am Heart Assoc Date: 2017-01-20 Impact factor: 5.501
Authors: Paul L Wood; Kathleen A Hauther; Jon H Scarborough; Dustin J Craney; Beatrix Dudzik; John E Cebak; Randall L Woltjer Journal: Life (Basel) Date: 2021-04-28
Authors: Danni Li; Jeffrey R Misialek; Clifford R Jack; Michelle M Mielke; David Knopman; Rebecca Gottesman; Tom Mosley; Alvaro Alonso Journal: Int J Mol Sci Date: 2019-04-09 Impact factor: 5.923
Authors: Paul L Wood; William Muir; Undine Christmann; Philippa Gibbons; Courtney L Hancock; Cathleen M Poole; Audrey L Emery; Jesse R Poovey; Casey Hagg; Jon H Scarborough; Jordon S Christopher; Alexander T Dixon; Dustin J Craney Journal: Poult Sci Date: 2020-11-17 Impact factor: 3.352
Authors: Jovia L Nierenberg; Jiang He; Changwei Li; Xiaoying Gu; Mengyao Shi; Alexander C Razavi; Xuenan Mi; Shengxu Li; Lydia A Bazzano; Amanda H Anderson; Hua He; Wei Chen; Jack M Guralnik; Jason M Kinchen; Tanika N Kelly Journal: Aging (Albany NY) Date: 2020-06-01 Impact factor: 5.682